banner
PDGFR inhibitor Imatinib mesylate, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ126

PDGFR inhibitor Imatinib mesylate, Purity ≥98%

Synonym: 220127-57-1; PDGFR inhibitor; Gleevec; Glivec; CGP-57148B; STI-571

  • MDL: MFCD04307699
  • CAS Number: 220127-57-1
  • Compound CID: 123596
img
Product Size
100 mg; 200 mg; 500 mg
Price
Datasheet
MSDS
Properties
Description
Imatinib mesylate, soluble in DMSO and water and insoluble in ethanol, blocks the activity of platelet-derived growth factor receptors (PDGFR), which play a crucial role in cell growth, angiogenesis, and tissue. It targets c-Kit (M-07e cells), PDGFR, and v-Abl.
Molecular Weight
589.7
Molecular Formula
C29H31N7O.CH4SO3
Targets
c-Kit (M-07e cells): 100 nM; PDGFR: 100 nM; v-Abl: 600 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 101 mg/mL (171.26 mM); Water: 101 mg/mL (171.26 mM); Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Imatinib mesylate is applied as a PDGFR inhibitor in research focused on cancer treatment mechanisms involving PDGFR blockade.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0